Vitality Watch

Dossier clinicaltrials trial early 17-aug-2026
Small or early-phase human trial or pilot study

Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life

Key claim: The LONG-LIFE Phase I trial will test whether one to three 25 mg psilocybin doses change aging-related biomarkers, cognitive function, and purpose/meaning in life versus wait-list in medically stable adults aged 60–80.

Abstract

The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults.

Up to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.

Findings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.

Why this matters

The LONG-LIFE trial marks a shift in the psychedelics field from psychiatric indications toward explicit healthy-aging endpoints — biomarkers, cognition, and existential measures like purpose in life — in a 60–80 population. It signals that psychedelics are being drawn into the longevity trend orbit, but at Phase I dose-ranging stage the evidence is protocol-only; the trend is running well ahead of any outcome data.

Source

Link

Briefing card

Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
Stage: trial early · clinicaltrials · 17-aug-2026

The LONG-LIFE Phase I trial will test whether one to three 25 mg psilocybin doses change aging-related biomarkers, cognitive function, and purpose/meaning in life versus wait-list in medically stable adults aged 60–80.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07719088

build build 880 · 2bcef25 · 2026-11-18